Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Clavamox vs Augmentin in Healthy Volunteers
NCT03702894Phase 1Completed
- Sponsor
- Pharmtechnology
- Start
- Sep 2018
- Primary completion
- Oct 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of clavulanic acid in bacterial infection (2 arms), sponsored by Pharmtechnology. Primary endpoints: Cmax of amoxicillin for the test and the reference products at 10.00 hours, AUC0-t of amoxicillin for the test and the reference products and 2 more. Started Sep 2018; status: completed.
02
Drugs
clavulanic acid
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT03702894.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03702894.